Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers, includes gallery
News from Reuters Biopharma: Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers, includes gallery
Dyne Therapeutics
Dyne Therapeutics (NASDAQ: DYN) is a clinical-stage muscle disease company developing targeted therapeutics for genetically driven muscle disorders including Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). Its FORCE platform delivers oligonucleotides to muscle tissue.
Company Info
Sector:RNA Therapeutics / Genetic Medicine
Headquarters:Waltham, Massachusetts, USA
Founded:2018
Website:www.dyne-tx.com/
Recent News
Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review
Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review.